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Background: This is the first study to examine the effect of acute (24-hour) b-blocker withholding on
ventilatory efficiency in patients with advanced chronic heart failure (CHF) during maximal incremental
treadmill cardiopulmonary exercise test.
Methods and Results: Seventeen CHF patients were studied either 3 hours after administration of
b-blocker (BBON) or 27 hours after the last b-blocker ingestion (BBOFF). The ventilatory efficiency
was measured via the slope of the linear relationship between ventilation (V0E) and carbon dioxide pro-
duction (V0CO2) (ie, V0E/V0CO2 slope). Measurements were also made at rest, anaerobic threshold
(AT), maximal end-tidal pressure for carbon dioxide (PETCO2max), respiratory compensation point
(RC), and peak exercise. Compared with BBON, the V
0
E/V
0CO2 slope was significantly increased during
BBOFF (30.8 6 7.4 vs. 29.1 6 5.4, P 5 .04). At peak exercise, oxygen uptake (V
0O2, 16.0 6 2.7 vs. 15.6
6 2.8 mL$kg$min) and V0CO2 (1458 6 459 vs. 1414 6 429 mL/min) were not different between the 2
conditions, whereas V0E was higher during BBOFF (49.5 6 10.7 vs. 46.1 6 9.6 L/min, P 5 .04). No dif-
ferences were noted at AT and RC in V0O2, V0CO2, V0E, V0E/V0O2, and V0E/V0CO2 ratios during the 2 con-
ditions. At PETCO2max, used to noninvasively estimate the CO2 set point, V
0
E was higher (33.9 6 7.6 vs.
31.76 7.3 L/min, P5 .002) and PETCO2 was lower (37.46 4.8 vs. 38.56 4.0 mm Hg, P5 .03), whereas
V0CO2 was unchanged (1079 6 340 vs. 1050 6 322 mL/min) during BBOFF.
Conclusion: Acute b-blocker withholding resulted in decreased ventilatory efficiency mostly from an
increase of V0CO2-independent regulation of V0E and less likely from a change in ventilation/perfusion
mismatching. (J Cardiac Fail 2010;16:548e555)
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548heart failure (CHF) often present with an impaired ventila-
tory response to exercise.2e4 In CHF, the V0E/V0CO2 slope
is a strong prognostic marker independent from other exer-
cise related heart failure prognostic markers such as peak
oxygen uptake (V0O2).
3,5
Long-term treatment with b-blockers has been shown to
reduce the V0E/V0CO2 slope in patients with CHF during
exercise.6,7 Although the precise mechanism(s) underlying
this improvement remain to be fully elucidated, ameliora-
tion of ventilation/perfusion mismatching,6 as well as regu-
lation of the partial arterial pressure of carbon dioxide
(PaCO2) set point (which is in part controlled by sympa-
thetic nervous system activity7,8) have been advocated as
potential contributory factors.6,7
Of note, acute hemodynamic effects of b-blocking are
often deleterious with a fall in ejection fraction and rise in
peripheral vascular resistance in patients with CHF,9,10
whereas the chronic effect of changes in b-receptor
density11e14 may best explain the observed benefits on
cardiac structure and clinical outcomes.15,16 Indeed,
b-blockers exert many acute and chronic effects on both
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cardiac and noncardiac receptors including ventricular
b-adrenoceptors,12e14 as well as chemo-, metabo-, and
ergo-receptors in the peripheral muscles indirectly via
sympathetic system activation.6e8
In principal, the improved ventilatory efficiency seen
after long-term treatment could be due to acute as well as
chronic effects of b-blockers. Accordingly, we examined
the effect of 24-hour b-blocker withholding on ventilatory
efficiency in patients with advanced CHF during maximal
incremental treadmill cardiopulmonary exercise test and
compared our data on acute b-blocker withholding with his-
torical published data on chronic (2-month) b-blocker with-
holding from Agostoni and coworkers7 to find out whether
a unified mechanism could explain the effect of acute and




All patients with advanced systolic CHF, in New York Heart
Association Class II-IV, on stable medical therapy including
b-blockers for at least 3 months referred for cardiopulmonary
exercise tolerance testing (CPET) were screened for participation
in the study from March 2008 through December 2008. Patients
with atrial fibrillation, inability to exercise, hospital admission
for heart failure, or acute coronary syndrome in the past 90 days
or with symptoms of myocardial ischemia were excluded. Also
excluded were patients with other medical conditions, such as
respiratory diseases, primary pulmonary hypertension, or neuro-
muscular and orthopedic diseases, which could cause or contribute
to exercise intolerance. The study was approved by the institu-
tional review board of New York Presbyterian Hospital, Columbia
University Medical Center. Informed consent was obtained from
all participants.
Study Design
This was a randomized, parallel, crossover study. Each partici-
pant performed 2 CPETs at 10 am in the morning conducted 5 to 7
days apart. Subjects were instructed to either take b-blockers
3 hours before the visit or to withhold b-blockers following the
7 am dose on the preceding day. Accordingly, 1 test was con-
ducted 3 hours after administration of b-blocker (BBON), whereas
the other test was performed 27 hours after the last b-blocker
ingestion (BBOFF). BBON and BBOFF visits were performed in ran-
dom order to eliminate possible training effects. The investiga-
tor(s) responsible of performing CPET was not involved in the
analysis of the results.
CPET
During each visit, patients underwent a symptom-limited incre-
mental treadmill CPET. The work rate increased continuously as
a ramp function by augmenting the speed and grade of the treadmill
according to amodifiedNaughton protocol. Patients were instructed
to exercise until the point of symptom limitation. Patients were
strongly encouraged to perform amaximal test, but they determined
when their symptoms were so severe that it was necessary to stop -
exercising. Resting heart rate (HR) was obtained after 30minutes of
rest in a quiet, temperature-controlled room. Electrocardiographicmonitoring of HR, rhythm, and ST-segment changes were recorded
continuously at rest and throughout exercise testing, whereas blood
pressure (by indirect sphygmomanometry) was collected at rest, ev-
ery 2 minutes during exercise, and upon completion of exercise.
Cardiopulmonary and breathing pattern measurements were col-
lected in a breath-by-breath fashionwhile subjects breathed through
a mouthpiece with attached low-resistance flow transducer with na-
sal passages occluded by a nose clip using aMedgraphics metabolic
cart (Medical Graphics Corporation St. Paul, MN). V0E, V0O2,
V0CO2, end-tidal oxygen and carbon dioxide partial pressure
(PETO2 and PETCO2, respectively), tidal volume (VT), and respira-
tory frequency (Rf ) were calculated. Exercise variables were mea-
sured continuously and averaged over the last 20 seconds of each
minute and at peak exercise, defined as the last 20 seconds of loaded
exercise. The instrumentswere calibrated before every test andwere
corrected for humidity, room temperature, and barometric pressure,
according to the manufacturer’s protocol. Peak V0O2 (V0O2peak) and
peakV0E (V0Epeak) were defined, respectively, as the highest value of
V0O2 and V0E that could be sustained for at least 20 seconds during
the last stage of exercise when the respiratory exchange ratio (RER)
wasO1.0. Metabolic and cardioventilatory variables were reported
according to formulas as previously described.17
The anaerobic threshold (AT ) was detected individually using the
V-slopemethod and verified against other points; that is, the V0O2 at
which the ventilatory equivalent for oxygen (V0E/V0O2) begins to in-
crease systematically without an increase in the ventilatory equiva-
lent for carbon dioxide (V0E/V0CO2) and where PETO2 begins to
increase without a decrease in PETCO2.
18 The respiratory compen-
sation point (RC ) was calculated as the point where the slope of the
V0E/V0CO2 relationship started to increase.
18 The maximal PETCO2
was defined as the highest value of PETCO2 observed during exer-
cise test, between the AT and the RC point, when PETCO2 remains
constant.18 This was done to evaluate the CO2 set point, which
can be noninvasively estimated by the PETCO2 during exercise
before the metabolic compensation point is reached. Exercise
capacity was assessed by measuring the V0O2 at AT and peak. Mis-
matching of the heart and lungs was evaluated via the ventilatory
efficiencymeasure V0E/V0CO2 slope (ie, the slope of the linear rela-
tionship between V0E and V0CO2 from 1 minute after the beginning
of loaded exercise to the end of the isocapnic buffering period).18
Two blinded experienced readers independently interpreted each
test, and the results were averaged.
For statistical analysis purposes, 5 main points were used for eval-
uation of exercise parameters: 1) pre-exercise rest (baseline), defined
as the steady-state period after at least 3 minutes of breathing on the
mouthpiece while being at rest before the start of exercise; 2) AT; 3)
maximal PETCO2; 4) RC point; and 5) peak exercise.
Statistical Analysis
Results were expressed as means 6 SD. A P! .05 level of sta-
tistical significance was used for all analyses. The current study’s
group responses at different exercise level points during treadmill
exercise (baseline, AT, RC, maximal PETCO2, and peak) were
compared using paired t-tests with appropriate Bonferroni adjust-
ments for multiple comparisons. Comparisons between data from
the current study and those from Agostoni et al were made using
unpaired t-tests. Repeated measurement analysis was not per-
formed because we were interested in treatment effects at specific
exercise points/levels rather than in interactions between treatment
and time over the course of the exercise test. Pearson correlations
were used to establish associations between dependent variables
such as peak V0E, V0E/V0CO2 slope and ratios, and relevant
550 Journal of Cardiac Failure Vol. 16 No. 7 July 2010independent variables, such as HR and rest-to-peak difference in
HR (DHR) and any other measured cardiopulmonary variables.
Results
Subjects’ characteristics are summarized in Table 1.
Cardiovascular Response to CPET
Differences in cardiovascular responses at rest and at
peak exercise after BBOFF compared with BBON are shown
in Table 2. Based on Weber classification of severity,19,20
1 patient presented with V0O2 at AT O14 mL$min$kg
and V0O2 peak O20 mL$min$kg (Class A, little or no im-
pairment), 9 patients with V0O2 at AT falling between 11
and 14 mL$min$kg and V0O2 peak between 16 and 20
mL$min$kg (Class B, mild-to-moderate impairment),
whereas 7 patients presented with V0O2 at AT falling
between 8 and 11 mL$min$kg and V0O2 peak between
10 and 16 mL$min$kg (Class C, moderate-to-severe impair-
ment) during BBOFF. BBON did not affect exercise capacity;
V0O2 peak, V0O2 at AT and time to exhaustion were unaf-
fected by BBON (Tables 2, 3). BBOFF patients presented
at rest with higher HR, by 6 6 6 beats/min (w8%, P 5
.0006), compared with BBON patients, but with no differ-
ence in resting V0O2 (Table 2). BBOFF patients stopped ex-
ercise at higher HR, by 9 6 11 beats/min (w7-8%, P 5
.003), but with no difference in peak V0O2 (Table 2). HR
and V0O2 values at AT, maximal PETCO2, and RC point af-
ter b-blockers withholding compared with BBON are shown
in Table 3. Rest-to-peak changes in HR ranged from 50 6
21 beats/min during BBOFF session to 47 6 17 beats/min
during BBON session.
Ventilatory Response to CPET
b-blocker withholding did not affect V0E at rest, nor at AT
or at RC point (Tables 2, 3). At peak exercise, V0E was in-
creased by 3.5 L/min (by 7%, P 5 .04) in the presence of
no differences in V0CO2, VT, and Rf after b-blockerTable 1. Subjects’ Characteristics (n 5 17)
Male:Female 11:6
Age, y 51 6 11
Height, cm 170 6 11
Weight, kg 86 6 21
Body mass index, kg/m2 30 6 6











LVEF, left ventricular ejection fraction; ICM, ischemic cardiomyopathy;
NICM, nonischemic (idiopathic) cardiomyopathy; ACE inhibitor,
angiotensin-converting enzyme inhibitor; ARB, angiotensin receptors
blockers; AA, antialdosterone agents.
Values are means 6 SD.withholding compared with BBON (Table 2). Rest-to-peak
changes in V0E ranged from 39.2 6 9.5 L/min during
BBOFF session to 35.9 6 9.3 L/min during BBON session.
At maximal PETCO2, which was observed between the
AT and the RC point, V0E was 2.2 L/min higher (P 5
.002) and PETCO2 1.1 mm Hg lower (P 5 .03), whereas
V0CO2 was not significantly changed after b-blocker with-
holding (Table 3).
b-blocker withholding did also increase the V0E/V0CO2
slope by w5e6%, from the average value of 29.1 6 5.4
to the average value of 30.8 6 7.4 (P 5 .04) (Fig. 1). Based
on Arena ventilatory class (VC) system,21 9 patients pre-
sented with V0E/V0CO2 slope #29.9 (VC I), 6 patients
with V0E/V0CO2 slope between 30.0 and 35.9 (VC II), 1 pa-
tient with V0E/V0CO2 slope between 36.0 and 44.9 (VC III),
and 1 patient with V0E/V0CO2 slope $ 45.0 (VC IV) during




slope # 29.9 (VC I), 4 patients a V0E/V0CO2 slope between
30.0 and 35.9 (VC II), and 2 patients a V0E/V0CO2 slope
between 36.0 and 44.9 (VC III), whereas no one showed
a V0E/V0CO2 slope $ 45.0 (VC IV).
The ventilatory equivalents for oxygen and carbon dioxide
(V0E/V0O2 and V0E/V0CO2, respectively) were not signifi-
cantly different during BBOFF session compared with
BBON session at rest and at peak exercise (Table 2), as well
as at AT (V0E/V0O2 5 30 6 7 vs. 29 6 5; V0E/V0CO2 5 32
6 7 vs. 32 6 5), and at RC point (V0E/V0O2 5 34 6 11 vs.
32 6 7; V0E/V0CO2 5 33 6 8 vs. 32 6 6) (Table 3). No
differences were also found in PETO2 and PETCO2 values at
the previously mentioned levels of exercise in both sessions.
Both V0E/V0O2 and V0E/V0CO2 ratios werew2 units higher
during BBOFF sessions at maximal PETCO2 because of the
higher V0E at this level of exercise (Table 3).
Correlates of Improvement
The difference (D) in peak HR between BBOFF and
BBON, an indicator of sinoatrial b1-receptor blockade,
22
did not correlate with the D in V0E/V0CO2 slope between
BBOFF and BBON (r 5 -0.27, P 5 .3) (Fig. 2A), nor with
the D in peak V0E between BBOFF and BBON (r 5 e0.23,
P 5 .4) (Fig. 2B). The D peak HR did not correlate with
D peak V0O2, expressed either as mL/min (r 5 0.25, P 5
.3) or as mL$kg$min (r 5 0.31, P 5 .2). The D peak V0E
and D V0E/V0CO2 slope correlated both with D peak PET-
CO2 (r 5 0.826, P 5 .00004 and r 5 0.791, P 5
.0002, respectively). Of note, the D V0E/V0CO2 slope also
correlated with D maximal PETCO2 (r 5 0.64, P 5
.007), and D V0E measured at maximal PETCO2 correlated
with D maximal PETCO2 (r 5 0.56, P 5 .03) (Fig. 3A,
B). The D V0E/V0CO2 slope did not correlate with D peak
V0O2, expressed either as mL/min (r 5 0.38, P 5 .1) or
as mL$kg$min (r 5 0.46, P 5 .06).
Comparison with Historical Controls
We decided to compare our data on acute b-blocker with-
holding with historical published data on chronic (2-month)
Table 2. Metabolic and Cardiorespiratory Responses to CPET in CHF Patients (n 5 17) with (BBON) and without b-blockers
(BBOFF)
Rest Peak
Variables BBOFF BBON BBOFF BBON
Time, seconds d d 953 6 188 967 6 162
V0O2, mL/min 308 6 101 280 6 75 1391 6 460 1342 6 393
V0O2/kg 3.6 6 0.8 3.4 6 1.1 16.0 6 2.7 15.6 6 2.8
V0CO2, mL/min 262 6 85 255 6 92 1458 6 459 1414 6 429
RER 0.85 6 0.06 0.90 6 0.1 1.1 6 0.1 1.1 6 0.1
HR, beats/min (% pred) 73 6 13 (44 6 9) 67 6 13* (40 6 8)* 123 6 18 (73 6 10) 114 6 16* (68 6 9)*
O2 pulse, mL/beat 4.4 6 2.2 4.3 6 1.6 11.3 6 3.1 11.9 6 3.5
V0E, L/min 10.3 6 2.8 10.2 6 3.8 49.5 6 10.7 46.1 6 9.6*
Rf (breaths/min) 19 6 6 17 6 6 38 6 9 37 6 10
VT, L 0.59 6 0.23 0.64 6 0.29 1.34 6 0.32 1.32 6 0.37
V0E/V0O2 ratio 34 6 6 36 6 8 38 6 14 36 6 11
V0E/V0CO2 ratio 40 6 7 41 6 7 36 6 10 34 6 8
PETO2 108 6 7 108 6 8 113 6 9 112 6 7
PETCO2 34.4 6 3.0 34.1 6 3.5 34.1 6 6.4 35.2 6 4.7
CPET, cardiopulmonary exercise tolerance testing; CHF, chronic heart failure; BBON, 3 hours after administration of b-blocker; BBOFF, 27 hours after the
last b-blocker ingestion; V0O2, oxygen uptake; V0CO2, carbon dioxide production; RER, respiratory exchange ratio; HR, heart rate; V0E, ventilation; Rf, re-
spiratory frequency; VT, tidal volume; PETO2, end-tidal partial pressure for oxygen; PETCO2, end-tidal partial pressure for carbon dioxide.
Values are means 6 SD.
*P ! .05.
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anism could explain the effect of acute and chronic
b-blocker withholding on ventilatory efficiency in CHF
patients.
We compared data of 14 of the 17 subjects of the present
experiment who were on carvedilol with historical and pre-
viously published data of 8 CHF patients who were studied
after chronic (2-month) b-blocker withholding by Agostoni
and coworkers (Fig. 1, Group B, from reference 7). Indeed,
we had access and reanalyzed the Agostoni et al data to
evaluate only those patients who had prolonged (2-month)
b-blocker withdrawal. Therefore, the 14 patients of the
present study were comparable with 8 CHF patients on car-
vedilol provided by Agostoni and coworkers (Fig. 1, Group
B, from reference 7).
Our patients were well matched to Agostoni’s cohort
with respect to age (49 6 8 vs. 50 6 9, respectively, P 5
.8), peak V0O2 (15.9 6 3.0 vs. 16.5 6 3.8, respectively, P
5 .7), peak HR (72 6 11 vs. 78 6 15% predicted, respec-
tively, P 5 .4), peak V0E (49.6 6 9.9 vs. 45.5 6 14.5, re-
spectively, P 5 .5), and V0E/V0CO2 slope (31.6 6 7.9 vs.
30.6 6 3.9, respectively, P 5 .7) in the BBOFF condition,
as well as in the BBON condition (peak V
0O2 5 15.5 6
2.9 vs. 17.7 6 7.1, respectively, P 5 .4; peak HR 5 68
6 10 vs. 72 6 16% predicted, respectively, P 5 .6; peak
V0E 5 45.8 6 8.6 vs. 43.6 6 19.2, respectively, P 5 .8),
and V0E/V0CO2 slope 5 29.4 6 5.9 vs. 26.8 6 3.8, respec-
tively, P 5 .2). When analyzing both groups separately or
in combination, the difference (D) in peak HR between
BBOFF and BBON did not correlate with the D in V
0
E/
V0CO2 slope between BBOFF and BBON, nor with the D
in peak V0E between BBOFF and BBON (Fig. 4A, B). The
D peak HR did not correlate with D peak V0O2, expressed
either as mL/min or as mL$kg$min (r 5 0.19, P 5 .4
and r 5 0.28, P 5 .2, respectively). The D peak V0E andD V0E/V0CO2 slope correlated both with D peak PETCO2
(r 5 0.82, P 5 .000003 and r 5 0.73, P 5 .0001, re-
spectively). Of note, the D V0E/V0CO2 slope also correlated
with D maximal PETCO2 (r 5 0.55, P 5 .01). The D V0E/
V0CO2 slope did not correlate with D peak V0O2, expressed
either as mL/min or as mL$kg$min (r 5 0.07, P 5 .7 and
r 5 0.01, P 5 .9, respectively).
Discussion
The main findings of this study are as follows. 1) Acute
b-blocker withholding worsened ventilatory efficiency in
CHF patients during exercise; 2) acute b-blocker withhold-
ing did not modify the ventilation/perfusion mismatching
during exercise; 3) acute b-blocker withholding was associ-
ated with an increase of reflex regulation of V0E (V0CO2-
independent); and 4) correlative analysis did not show an
association between change in peak HR and change in
peak V0E or in V0E/V0CO2 slope.
Based on Weber classification of severity,19,20 our
patients with advanced CHF demonstrated mild-to-severe
exercise intolerance which was not affected by acute b-
blocker withholding (V0O2/kg peak, 15.6 6 2.8 vs. 16.0
6 2.7; Table 2). We were satisfied that the reduced exercise
performance in our CHF patients was not the result of
reduced motivational effort: under both conditions, patients
reported intolerable exertional symptoms at the peak of
exercise and showed an RER O1.0 at peak exercise.
During exercise,V0Ewas higher at peak (by 3.5L/min,P5
.04) and at maximal PETCO2 (by 2.2 L/min, P 5 .002), and
V0E/V0CO2 slope was steeper (30.8 6 7.4 vs. 29.1 6 5.4, P
5 .04) in CHF patients after acute b-blocker withholding
(Fig, 1). We considered the following potential contributors
to reduced ventilatory efficiency after acute b-blocker with-










































































































































































































































































































































































































































































































































































































































































































































































































552 Journal of Cardiac Failure Vol. 16 No. 7 July 2010oxygen delivery/utilization; 2) increased ventilation/perfu-
sion mismatching, reflecting reduced cardiac output or in-
creased central venous distension/congestion; 3) decrease
in CO2 set point, caused by the reversion to the overactive
chemo- and metabo- and ergo- reflexes, which are driven
by the sympathetic nervous system activity; or 4) a combina-
tion of these.
In the current study, acute b-blocker withholding did not
delay the occurrence of the anaerobic threshold and V’O2
and V0E measured at this point (Table 3) were not different
between the 2 conditions, suggesting that the reduced ven-
tilatory efficiency was unlikely to be related to an early
local metabolic acidosis that, in turn, would have reflected
a reduced oxygen delivery/utilization to the peripheral exer-
cising muscles.
One possible explanation for our findings may lie in the
pulmonary vasodilatory effect of b-blocker, especially car-
vedilol, because of its a-blocking properties (14 of 17
patients were on carvedilol).23 Upon withdrawal, pulmo-
nary vasoconstriction may occur; therefore, pulmonary per-
fusion may decrease, leading to a ventilation/perfusion
mismatching, which would in turn increase the V0E/
V0CO2 slope.
6,7,17,24 However, it should be noted that acute
b-blocker withholding was associated with consistent
increase in V0E/V0CO2 slope in the absence of any measur-
able deterioration in pulmonary gas exchange; both PETO2
and PETCO2 were preserved at rest, at AT, at RC and at peak
exercise (Tables 2, 3). The V0E/V0O2 and V0E/V0CO2 ratios
were also not different throughout exercise under the 2 con-
ditions (Tables 2, 3), thus suggesting that the increased ven-
tilatory requirement observed after acute b-blocker
withholding was less likely to reflect the increased ventila-
tion/perfusion mismatching as a result of reduced ability to
decrease a higher physiological dead space during exercise
due to reduced pulmonary perfusion. Of note, VT expansion
during exercise did not differ under both conditions, thus
being unlikely that VT could also have contributed to the
high physiological dead space (Tables 2, 3).17Fig. 1. Individual ventilation (V0E) and carbon dioxide production
(V0CO2) slopes (V0E/V0CO2 slopes) are shown in all patients dur-
ing BBOFF (27 hours after the last b-blocker ingestion) and BBON
(3 hours after administration of b-blocker) conditions.
Fig. 2. (A) Correlation between the difference (delta) in peak heart rate (HR) between BBOFF (27 hours after the last b-blocker ingestion)
and BBON (3 hours after administration of b-blocker) and delta in ventilation (V
0
E) and carbon dioxide production (V
0CO2) slope (V0E/
V0CO2 slope) between BBOFF and BBON (r5 0.267, P5 .3) in our 17 chronic heart failure (CHF) patients (filled circles). (B) Correlation
between delta in peak HR between BBOFF and BBON and delta in peak V
0
E between BBOFF and BBON (r 5 0.226, P 5 .4) in our 17 CHF
patients (filled circles).
b-blocker and Ventilatory Efﬁciency in CHF  Laveneziana et al 553The steepness with which V0E rises with respect to
V0CO2 is also determined by the behavior of arterial CO2
tension and the V0CO2 during exercise. Having reasonably
excluded the previously mentioned mechanisms and given
that acute b-blocker withholding did not modify the
V0CO2 throughout exercise in our study, we can infer that
the slope of the V0E/V0CO2 relationship would have sub-
stantially increased if PaCO2 was driven down by a high
ventilatory drive from overactive peripheral chemorecep-
tors or by overactive metabo- or ergoreceptors in exercising
skeletal muscles. The CO2 set point can be noninvasively
estimated by the PETCO2 during exercise before the meta-
bolic compensation point is reached. This point, that we
called maximal PETCO2, is the highest value of PETCO2
recorded during an incremental exercise test, and was
observed between the AT and the RC point when the PET-
CO2 remains constant (Table 3). The observation that afterFig. 3. (A) Correlation between the difference (delta) in end-tidal partia
after the last b-blocker ingestion) and BBON (3 hours after administrati
lation (V0E) and carbon dioxide production (V0CO2) slope (V0E/V0CO2 s
chronic heart failure (CHF) patients (filled circles). (B) Correlation betw
between BBOFF and BBON both measured at maximal PETCO2 (r 5 0acute b-blocker withholding the recorded maximal PETCO2
was 1.1 mm Hg lower (P 5 .03) and V0E was 2.2 L/min
higher (P 5 .002) with an unchanged V0CO2 (Table 3)
strongly favors a decrease in CO2 set point, likely from
an increased excitatory inputs on V0E caused by the restora-
tion of the overactive chemo- and metabo- and ergo-
reflexes, which are driven by the sympathetic nervous
system activity.25e28
The contention that acute b-blocker withholding exerted
its effect more on chemo-, metabo-, or ergo-receptors rather
than on b1-blockade, is also supported by the lack of correla-
tion between delta peak HR (an excellent in vivo measure of
b-blockade22) and either delta peak V0E or delta V0E/V0CO2
slope (Fig. 2). Comparison of our data on acute (24-hour)
b-blocker withholding with historical data kindly provided
by Agostoni and colleagues (Fig. 1, Group B, from reference
7) on chronic (2-month) b-blocker withholding suggests thel pressure for carbon dioxide (PETCO2) between BBOFF (27 hours
on of b-blocker) measured at maximal PETCO2 and delta in venti-
lope) between BBOFF and BBON (r 5 0.64, P 5 .007) in our 17
een delta in PETCO2 between BBOFF and BBON and delta in V
0
E
.56, P 5 .03) in our 17 CHF patients (filled circles).
Fig. 4. (A) Correlation between delta in peak heart rate (HR) between BBOFF (27 hours after the last b-blocker ingestion) and BBON (3
hours after administration of b-blocker) and delta in ventilation (V0E) and carbon dioxide production (V0CO2) slope (V0E/V0CO2 slope)
between BBOFF and BBON (r 5 0.164, P 5 .5) in our 14 chronic heart failure (CHF) patients on carvedilol (filled circles) pooled
with the 8 CHF patients on carvedilol from Agostoni7 (filled triangles). (B) Correlation between delta in peak HR between BBOFF and
BBON and delta in peak V
0
E between BBOFF and BBON (r 5 0.226, P 5 .3) in our 14 CHF patients on carvedilol (filled circles) pooled
with the 8 CHF patients on carvedilol from Agostoni7 (filled triangles).
554 Journal of Cardiac Failure Vol. 16 No. 7 July 2010same mechanisms and interpretations (Fig. 4), ie, that the
decreased ventilatory efficiency is likely from an increase
of V0CO2-independent regulation of V0E.
Limitations
The number of patients of the present study is limited;
therefore, we must be very circumspect in any generaliza-
tion of our findings to the larger CHF population. The
lack of measurement of central hemodynamics and
PaCO2 during exercise precludes a definitive assessment
of the effect of acute (24-hour) b-blocker withholding on
ventilation/perfusion mismatching and on regulation of
CO2 set point during exercise. Our use of unpublished
data to evaluate a unified mechanism is somewhat unusual.
However, we feel it is acceptable as the unpublished data
derive from a previously published study7 and 1 of the
authors participated in the current study and can vouch
for the similarity of experimental conditions and data col-
lection as the present study.7 We believe the use of these
data is reasonable with the caveat that interpretation to
the larger heart failure population should be made with cau-
tion. Further studies that contain a larger sample size and
engage measurement of central hemodynamics and
PaCO2 during exercise will be required to definitively
elucidate the physiological mechanisms of the decreased
ventilatory efficiency after b-blocker withholding.
Conclusion
The current study extends previous studies on the phys-
iological mechanisms of b-blocker efficacy by exploring
the interaction between the ventilatory efficiency and ven-
tilation/perfusion mismatching and regulation of CO2 set
point during exercise. Our results suggest that both acuteand chronic b-blocker withholding produce decreased
ventilatory efficiency, mostly from an increase of
V0CO2-independent regulation of V0E and less likely
from a change in ventilation/perfusion mismatching.
Further studies are required to determine the clinical
implications of the pharmacologically induced interactions
that we have described.Disclosures
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